Jake Bauer - Feb 13, 2024 Form 4/A Insider Report for Enliven Therapeutics, Inc. (ELVN)

Role: Director
Signature: /s/ Ben Hohl, by power of attorney
Stock symbol: ELVN
Transactions as of: Feb 13, 2024
Transactions value $: $0
Form type: 4/A
Date filed: 2/20/2024, 07:26 PM
Date Of Original Report: Feb 15, 2024
Previous filing: Feb 27, 2023
Next filing: Feb 10, 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ELVN	Stock Option (right to buy)	Award	$0	+23.4K		$0.00	23.4K	Feb 13, 2024	Common Stock	23.4K	$14.85	Direct	F1, F2

Showing 1 to 1 of 1 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The original Form 4 filed February 15, 2024 incorrectly reported the number of shares subject to the option grant.
F2	100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2024 annual meeting of the Issuer's stockholders or (ii) the date of the 2025 annual meeting of the Issuer's stockholders, subject to the Reporting Person continuing as a non-employee director on the applicable vesting date.